Literature DB >> 7766943

Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria.

P Burgard1, M Armbruster, E Schmidt, A Rupp.   

Abstract

At the age of 13 years, 60 adolescents, suffering from phenylalaninemia due to hydroxylase deficiency, and their mothers were simultaneously investigated with a standardized psychiatric interview in order to determine the adolescents' psychiatric status. Forty symptoms related to emotional disorders, antisocial and conduct disorders, hyperkinetic syndromes, and specific symptoms like psychophysiological pains, enuresis, encopresis, tics, stereotypies, and eating disorders were examined. Severity level was rated as undisturbed, mild, moderate, and severe disturbance. Comparison with a representative sample of 191 age mates revealed a double rate of moderate disturbances for the PKU sample. There was no association between severity level and sex as well as mean phenylalanine level during the first 13 years of the patients' lives. No PKU specific diagnosis could be determined. WISC-R-IQ below 90 was associated with a threefold risk of more severe disturbance and patients with more than three adverse familial circumstances had a 50% chance of getting a psychiatric diagnosis. It is concluded that the observed disturbances result from stress associated more with the chronic condition than with the increased phenylalanine level.

Entities:  

Mesh:

Year:  1994        PMID: 7766943     DOI: 10.1111/j.1651-2227.1994.tb13467.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  12 in total

1.  Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury.

Authors:  M Dennis; L Lockyer; A L Lazenby; R E Donnelly; M Wilkinson; W Schoonheyt
Journal:  J Autism Dev Disord       Date:  1999-02

2.  Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls.

Authors:  J Weglage; M Grenzebach; M Pietsch; R Feldmann; R Linnenbank; J Denecke; H G Koch
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

3.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

4.  Family conditions and dietary control in phenylketonuria.

Authors:  G M Olsson; S M Montgomery; J Alm
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

5.  Quality of life in noncompliant adults with phenylketonuria after resumption of the diet.

Authors:  M Bik-Multanowski; B Didycz; R Mozrzymas; M Nowacka; L Kaluzny; W Cichy; B Schneiberg; J Amilkiewicz; A Bilar; M Gizewska; A Lange; E Starostecka; A Chrobot; B I Wojcicka-Bartlomiejczyk; A Milanowski
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

6.  Psychosocial aspects in phenylketonuria.

Authors:  J Weglage; B Fünders; K Ullrich; A Rupp; E Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria.

Authors:  E Schmidt; P Burgard; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.

Authors:  P Burgard; E Schmidt; A Rupp; W Schneider; H J Bremer
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria.

Authors:  G L Arnold; C J Vladutiu; C C Orlowski; E M Blakely; J DeLuca
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.